We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mayo Clinic: 56 Percent of FDA Accelerated Approvals for Oncology Drugs Rely on Unverified Surrogate Endpoints
Mayo Clinic: 56 Percent of FDA Accelerated Approvals for Oncology Drugs Rely on Unverified Surrogate Endpoints
A new study of oncology approvals shows that a majority of the candidates approved under accelerated review with surrogate endpoints lacked validation.